الفهرس 
ACUTE MYELOID LEUKEMIAOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
Summary
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by different recurrent cytogenetic aberrations that provide the most important prognostic information at diagnosis .
However, the prognosis for the majority of AML patients remains dismal, and identification of novel markers for risk stratification and therapeutic targeting is needed. One potential marker is the mutational status of Wilms tumor 1 (WT1). Acquired mutations of the WT1 gene have been reported in approximately 10% of AML patients
Relapse still remains an obstacle to successful allogeneic stem cell transplantation (SCT) for patients with acute leukemia. Early recognition of relapse at the molecular level provides a window for therapeutic intervention while the burden of disease is still relatively low .
However, for acute leukemia, there have been few studies on the association of minimal residual disease (MRD) levels with the occurrence of leukemic relapse after allogeneic SCT.
To overcome this difficulty, we performed frequent monitoring of MRD based on the expression levels of WT1, which hasbeen reported as a “panleukemic marker” for evaluating MRD in leukemia .
The aim of this study is to evaluate the prognostic value of WT-1 detection in patients with acute myeloid leukemia before and after allogeneic bone marrow transplants.
-100-
Patients in this study included 21 patients with acute myeloid leukemia (AML) who were admitted to the Nasser Institute, Ministry of Health .
All patients subjected to the following : complete history taking , clinical examination & complete blood picture , kidney function tests liver function tests & bone marrow aspiration for morphology and imunophenotyping and cytogenetic studies & qualitative PCR for detection of WT1 gene in AML pretransplant and post transplant .
This study revealed that there is no correlation between OS & DFS & haemoglobin level & platelets &gender&TLC & CD34 count&s.creatinine or ALT
This study revealed that there is no significance difference between pre allogenic BMT WT 1 expression and post allogenic BMT WT 1 expression in AML.
There is no relation between post allogenic BMT WT 1 and outcome .